Jennifer Van Eyk,
PhD Cedars-Sinai Medical Center
Talk Title: Medicine and Me: a route to individualized monitoring and intervention
Dr. Van Eyk is a Professor of Medicine at Cedars-Sinai Medical Center, Director of the Basic Science Research in the Barbra Streisand Woman’s Hearth Center and Director of the new Advance Clinical Biosystems Institute where she recently moved from Johns Hopkins University. Most recently she has become the co-director of the Cedars Sinai Precision Health, focused on in-hospital and population individualization of health care. Dr. Van Eyk is an international leader in the area of clinical proteomics and her lab has focused the developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.
Medicine and Me: a route to individualized monitoring and intervention
Qin Fu1*, Sarah Parker1*, Zongming Fu2*, Irene van den Broek1*, Vidya Venatraman1*, Ronald Holewinski1, Yue Wang3, David Herrington4, Jennifer E. Van Eyk1,2
1Cedars Sinai Medical Center, Los Angeles, CA, USA, 2Johns Hopkins University, Baltimore MD, USA, 3Virginia Institute of Technology, Arlington, VA, USA; 4 Wake Forest School of Medicine, Winston-Salem, NC, USA.
A premise of precision health is that continuous individual health monitoring will allow early disease detection, early intervention, increased quality of life and reduced health costs. Cardiovascular disease (CVD) remains a leading cause of mortality worldwide. Atherosclerosis, a primary CVD risk factor, begins early prior to clinical signs. We have focused on diagnosing early atherosclerosis by analyzing 100s of aortic and left anterior descending coronary arteries obtained from individuals (<50 years old) using DIA and DDA workflows. Using convex analysis of mixtures and differential dependent network modeling we defined the composition, network re-wiring and regulatory features associated with early atherosclerosis. Early atherosclerosis-tissue-secreted proteins were next quantified using a 72 protein MRM assay in plasma of individuals with varying degrees of CVD. Finally, using volumetric absorptive microsampling devices for remote blood collection and our robust automated sample preparation workflows we are carrying out continuous patent-centric screening of a mid-risk CVD population.